首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Balancing the evolution of radiotherapy quality assurance: in reference to Ford et al.
【24h】

Balancing the evolution of radiotherapy quality assurance: in reference to Ford et al.

机译:平衡放射治疗质量保证的发展:参考福特等人。

获取原文
获取原文并翻译 | 示例
           

摘要

In February 2007, a special symposium on quality assurance (QA) for radiation therapy, "Quality Assurance of Radiation Therapy: The Challenges of Advanced Technologies," was held. The 3-day program, which was sponsored jointly by the American Society for Therapeutic Radiology and Oncology (ASTRO), American Association of Physicists in Medicine (AAPM), and National Cancer Institute (NCI), included more than 40 invited speakers from the radiation oncology and industrial engineering/human factor communities. The consensus finding of the symposium was that the current process of developing consensus recommendations for prescriptive QA tests remains valid for many of the devices and software systems used in modern RT, although for some technologies, QA guidance is incomplete or out of date (1). This symposium represented a turning point for the radiation oncology community-namely, the transition from exclusive performance-based QA to process-based QA. This paradigm change has evolved because traditional performance-based QA does not prevent process-based errors (2, 3). The symposium presentations ranged from basic device-centered QA, such as linear accelerator QA (4) to methods for developing a systematic approach to quality improvement that incorporates a series of industrial engineering-based tools. The goal of the new approach is to: improve outcomes, reduce risk and/or improve patient safety, improve throughput, and reduce cost. This approach includes process mapping and process flowcharting, failure modes and effects analysis (FMEA), value stream mapping, and fault tree analysis (FTA) (5, 6). Symposium attendees came away empowered to deploy these new methods in their own clinic. However, it has taken a few years to see manuscripts that detail how an institution applied these methods and the outcome. The delay is for two reasons: radiation oncology departments must still perform the mundane, performance QA and have not been able to slow down to make the transition, and the initial analysis to asses FTAs is time-consuming, although not unmanageable. One such presentation by Ford et al. (7) is presented in this issue.
机译:2007年2月,举行了放射治疗质量保证(QA)专题研讨会,“放射治疗的质量保证:先进技术的挑战”。为期3天的计划由美国放射治疗与肿瘤学会(ASTRO),美国医学物理学家协会(AAPM)和美国国家癌症研究所(NCI)共同赞助,包括来自辐射的40多位演讲者肿瘤学和工业工程/人为因素社区。专题讨论会的共识发现是,为规范性QA测试制定共识建议的当前过程对于现代RT中使用的许多设备和软件系统仍然有效,尽管对于某些技术而言,QA指导不完整或已过时(1) 。该研讨会代表了放射肿瘤学界的一个转折点,即从基于性能的专有质量保证过渡到基于过程的质量保证。由于传统的基于性能的质量保证不能防止基于流程的错误(2,3),因此这种范式的变化已得到发展。研讨会的演讲范围从基本的以设备为中心的质量保证(例如线性加速器质量保证(4))到开发系统的质量改进方法的方法,该方法结合了一系列基于工业工程的工具。新方法的目标是:改善结果,降低风险和/或提高患者安全性,提高通量并降低成本。这种方法包括过程映射和过程流程图,故障模式和影响分析(FMEA),价值流映射以及故障树分析(FTA)(5、6)。参加研讨会的与会者可以在自己的诊所中部署这些新方法。但是,花了几年时间才能看到详细描述机构如何应用这些方法和结果的手稿。延迟的原因有两个:放射肿瘤学部门仍必须执行常规,执行质量检查并且不能放慢进度以进行过渡,并且对FTA进行初步分析是耗时的,尽管并非难以管理。福特等人的一个这样的演讲。 (7)在本期中提出。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号